Building flexibility into insulin replacement with insulin glargine

Insulin glargine ['Lantus'] is a long-acting insulin developed by Aventis Pharma which is administered once daily in patients with type 1 or 2 diabetes mellitus. Study data were reported at the 61st Annual Scientific Sessions of the American Diabetes Association [Philadelphia, US; June 2001], showing that the drug is as effective as insulin suspension isophane [NPH insulin], but associated with less hypoglycaemia. Hypoglycaemia often occurs with insulin suspension isophane therapy, leading to difficulties in optimising treatment.